Somewhat Positive News Coverage Somewhat Unlikely to Impact Mirati Therapeutics (MRTX) Share Price

Headlines about Mirati Therapeutics (NASDAQ:MRTX) have been trending somewhat positive recently, Accern reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mirati Therapeutics earned a news impact score of 0.11 on Accern’s scale. Accern also gave press coverage about the biotechnology company an impact score of 45.1036615588499 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Mirati Therapeutics (NASDAQ MRTX) traded down 2.04% during midday trading on Wednesday, hitting $4.80. The stock had a trading volume of 211,264 shares. Mirati Therapeutics has a 12 month low of $2.70 and a 12 month high of $7.22. The firm’s 50-day moving average price is $5.04 and its 200 day moving average price is $4.45. The company’s market cap is $119.85 million.

A number of equities research analysts have weighed in on MRTX shares. ValuEngine downgraded Mirati Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Jefferies Group LLC reiterated a “hold” rating and issued a $4.50 target price on shares of Mirati Therapeutics in a report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $7.75.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Zolmax and is the sole property of of Zolmax. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://zolmax.com/investing/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-mirati-therapeutics-mrtx-share-price/1639913.html.

This article was originally published by and is the sole property of Zolmax. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://zolmax.com/investing/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-mirati-therapeutics-mrtx-share-price/1639913.html

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company?s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Insider Buying and Selling by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Somewhat Critical News Coverage Somewhat Unlikely to Affect Chesapeake Granite Wash Trust  Stock Price
Somewhat Critical News Coverage Somewhat Unlikely to Affect Chesapeake Granite Wash Trust Stock Price
Curis, Inc.  Expected to Post Earnings of -$0.09 Per Share
Curis, Inc. Expected to Post Earnings of -$0.09 Per Share
Navios Maritime Midstream Partners  Given News Impact Rating of 0.30
Navios Maritime Midstream Partners Given News Impact Rating of 0.30
Unique Fabricating  Getting Somewhat Positive Press Coverage, Accern Reports
Unique Fabricating Getting Somewhat Positive Press Coverage, Accern Reports
Contrasting Federated Investors  & The Competition
Contrasting Federated Investors & The Competition
Reviewing Stryker Corporation  & Glaukos Corporation
Reviewing Stryker Corporation & Glaukos Corporation


Leave a Reply

 
© 2006-2017 Zolmax.